Ivyanskiy Ilya, Sand Carsten, Thomsen Simon Francis
Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
Case Rep Dermatol. 2012 Jan;4(1):19-26. doi: 10.1159/000336205. Epub 2012 Jan 30.
Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma; however, there is currently more and more data showing promising results in the management also of chronic urticaria. We present a case series of 19 patients with chronic urticaria treated in a university department with omalizumab and give an overview of the existing literature comprising an additional 59 cases as well as a total of 139 patients enrolled in two randomized controlled trials comparing omalizumab with placebo. The collective evidence points to omalizumab as a safe and effective treatment option for patients with chronic urticaria who do not sufficiently respond to standard therapy as recommended by existing guidelines.
奥马珠单抗是一种重组人源化单克隆抗体，可阻断IgE的高亲和力Fc受体。奥马珠单抗已被批准用于治疗中重度哮喘；然而，目前越来越多的数据表明，它在慢性荨麻疹的治疗中也显示出了有前景的结果。我们展示了一个在大学科室用奥马珠单抗治疗的19例慢性荨麻疹患者的病例系列，并概述了现有文献，其中包括另外59例病例以及参与两项比较奥马珠单抗与安慰剂的随机对照试验的总共139例患者。综合证据表明，对于那些对现有指南推荐的标准治疗反应不佳的慢性荨麻疹患者，奥马珠单抗是一种安全有效的治疗选择。
